Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint...

By Hossein Borghaei, MS, DO The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who...

Advocacy & Survivorship

The Lung Cancer Research Foundation and Free to Breathe Merge to...

Effective September 30, 2017, the Lung Cancer Research Foundation and Free to Breathe have merged organizations, with the goal of closing the funding gap...
- Advertisement -

Meeting News

Targeted Therapies Meeting Focuses on Upcoming Research Advances in Lung Cancer

By Chairs Suresh Ramalingam, MD, Paul Bunn, MD, PhD, Leora Horn, MD, MSc, and Roy Herbst, MD, PhD Lung cancer research has reached an exciting...